| 1.75 0.17 (10.76%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.34 | 1-year : | 2.74 |
| Resists | First : | 2 | Second : | 2.34 |
| Pivot price | 1.59  |
|||
| Supports | First : | 1.45 | Second : | 1.12 |
| MAs | MA(5) : | 1.66 |
MA(20) : | 1.5 |
| MA(100) : | 0.79 |
MA(250) : | 0.75 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1  |
| %K %D | K(14,3) : | 56.3 |
D(3) : | 57.5 |
| RSI | RSI(14): 60.5 |
|||
| 52-week | High : | 2 | Low : | 0.24 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OVID ] has closed below upper band by 26.4%. Bollinger Bands are 88.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.79 - 1.8 | 1.8 - 1.81 |
| Low: | 1.51 - 1.52 | 1.52 - 1.53 |
| Close: | 1.73 - 1.75 | 1.75 - 1.77 |
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Fri, 10 Oct 2025
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance
Thu, 09 Oct 2025
Ovid Therapeutics (OVID) Surges on Positive Analyst Rating - GuruFocus
Thu, 09 Oct 2025
Ovid spikes as Wedbush moves to Outperform on lead asset - Seeking Alpha
Tue, 07 Oct 2025
Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing - Sahm
Fri, 03 Oct 2025
Ovid Therapeutics Inc. (OVID) Stock: Soars on $81M Initial Funding, PIPE Could Reach $175M - CoinCentral
Fri, 03 Oct 2025
Ovid Therapeutics stock soars after positive results for epilepsy drug - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 5.952e+007 (%) |
| Held by Institutions | 16.3 (%) |
| Shares Short | 1,270 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.12e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -80.9 % |
| Return on Assets (ttm) | -26.8 % |
| Return on Equity (ttm) | -52.8 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 1746.28 |
| Sales Per Share | 1.9e+007 |
| EBITDA (p.s.) | 1.9e+007 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.77 |
| Dividend | 0 |
| Forward Dividend | 680030 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|